Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia; Department of Neurology, Alfred Health, Melbourne, VIC, Australia
Auto-generated profile, based on publicly available information
Miriam Wronski
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, VIC, Australia; Department of Neurology, Alfred Health, Melbourne, VIC, Australia
FGfor the Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group
for the Cerebral Venous Sinus Thrombosis With Thrombocytopenia Syndrome Study Group
+72
Background: Cerebral venous thrombosis (CVT) due to vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe condition, with high in-hospital mortality rates. Here, we report clinical outcomes of patients with CVT-VITT after SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccination who survived initial hospitalization. Methods: We used data from an international registry of patients who developed CVT within 28 days of SARS-CoV-2 vaccination, collected until February 10, 2022. VITT diagnosis was classified based on the Pavord criteria. Outcomes were mortality, functional independence (modified Rankin Scale score 0–2), VITT relapse, new thrombosis, and bleeding events (all after discharge from initial hospitalization). Results: Of 107 CVT-VITT cases, 43 (40%) died during initial hospitalization. Of the remaining 64 patients, follow-up data were available for 60 (94%) patients (37 definite VITT, 9 probable VITT, and 14 possible VITT). Median age was 40 years and 45/60 (75%) patients were women. Median follow-up time was 150 days (interquartile range, 94–194). Two patients died during follow-up (3% [95% CI, 1%–11%). Functional independence was achieved by 53/60 (88% [95% CI, 78%–94%]) patients. No new venous or arterial thrombotic events were reported. One patient developed a major bleeding during follow-up (fatal intracerebral bleed). Conclusions: In contrast to the high mortality of CVT-VITT in the acute phase, mortality among patients who survived the initial hospitalization was low, new thrombotic events did not occur, and bleeding events were rare. Approximately 9 out of 10 CVT-VITT patients who survived the acute phase were functionally independent at follow-up.
27 November 2025 in Transplantation and Cellular Therapy
Cognitive dysfunction is a common manifestation of immune effector cell-associated neurotoxicity syndrome (ICANS) following chimeric-antigen receptor (CAR) T-cell therapy. With CAR-T therapy indications rapidly expanding beyond traditional indications, it has become increasingly important to understand CAR-T therapy-related neurotoxicity and cognitive impairment to optimise treatment safety, and to improve monitoring and management. This study examined the Repeatable Battery of the Assessment of Neuropsychological Status (RBANS) as a tool for monitoring subacute cognitive recovery. In this prospective, single-centre cohort study, patients undergoing CAR T-cell therapy at The Alfred Hospital in Melbourne were evaluated with the RBANS at Day+1, Day+7, and a subacute outpatient visit (median 45 days post-infusion, IQR: 38 - 52). 238 RBANS administrations were conducted on eighty-seven patients (63% male, mean age of 66.2 years at infusion). Thirty (34%) patients developed ICANS. General linear mixed-effects models found significant time by ICANS group interactions. Post-hoc comparisons revealed that the ICANS group demonstrated significantly worse Attention, Language, and Total Index scores at Day+7, and significantly worse Total Index score at subacute review compared to the no ICANS group. Supplementary analyses also demonstrated that the higher grade (Grades 3 and 4) ICANS group performed worse than low-grade (Grades 1 and 2) and no ICANS groups. Patients who developed ICANS demonstrated deficits in attention and language. These cognitive deficits may persist for more than 45 days post-infusion in some patients. The RBANS shows potential as a valid measure of ICANS-related cognitive dysfunction, which can be used at the bedside and in clinic, as well as in research settings.